Related Experiment Videos
Severe hepatotoxicity associated with bromfenac sodium
P L Moses1, B Schroeder, O Alkhatib
1Department of Medicine, University of Vermont College of Medicine, Burlington 05401, USA.
The American Journal of Gastroenterology
|May 11, 1999
Summary
Prolonged use of bromfenac, a nonsteroidal anti-inflammatory drug, led to severe liver damage and failure in a patient. This case highlights the potential hepatotoxicity of bromfenac, even with short-term use.
Area of Science:
- Hepatology
- Pharmacology
- Toxicology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
- Drug-induced liver injury (DILI) is a significant concern with NSAID use.
- Bromfenac is an NSAID known for its potential adverse effects.
Observation:
- A 40-year-old woman developed subacute hepatitis and liver failure after one month of bromfenac treatment.
- Standard hepatitis and autoimmune markers were negative.
- Liver biopsy revealed submassive hepatic necrosis.
Findings:
- Bromfenac was identified as the causative agent for severe hepatotoxicity.
- The patient experienced complications including encephalopathy, fluid retention, and spontaneous bacterial peritonitis.
- Recovery occurred over three months with supportive care.
Implications:
- This case underscores the risk of severe liver injury from bromfenac.
- Clinicians should consider bromfenac-induced hepatotoxicity in patients presenting with liver failure.
- Further pharmacovigilance is warranted for bromfenac and similar NSAIDs.